Clinical Trial

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 5, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of sintilimab as adjuvant therapy in node-positive esophageal squamous cell carcinoma after radical surgery without neoadjuvant therapy. The main question it aims to answer is: • Efficacy of sintilimab as adjuvant therapy Participants will receive sintilimab 200 mg once on day 1, every 21 days(Q3W).
Trial Details
NCT Number NCT06190639
Lead Sponsor Zhejiang Cancer Hospital
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 31 participants
Start Date 2023-10-25
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-01-05